Lund-Johansen F(2023) A strong case for third-party testing Elife, 12 DOI 10.7554/eLife.93329, PubMed 37962204
Kared H, Alirezaylavasani A, Lund KP, Chopra A, Tietze L, de Matos Kasahara T, Goll GL, Grødeland G, Kaarbø M, Reisæter AV, Hovd M, Heldal K, Vaage JT, Lund-Johansen F, Midtvedt K, Åsberg A, Munthe LA(2023) Hybrid and SARS-CoV-2-vaccine immunity in kidney transplant recipients EBioMedicine, 97, 104833 DOI 10.1016/j.ebiom.2023.104833, PubMed 37844534
Foldvari Z, Knetter C, Yang W, Gjerdingen TJ, Bollineni RC, Tran TT, Lund-Johansen F, Kolstad A, Drousch K, Klopfleisch R, Leisegang M, Olweus J(2023) A systematic safety pipeline for selection of T-cell receptors to enter clinical use NPJ Vaccines, 8(1), 126 DOI 10.1038/s41541-023-00713-y, PubMed 37607971
Contact information: Group leader Fridtjof Lund-Johansen, Department of Immunology, Oslo University Hospital, Rikshospitalet, Tel: +47 23073016, E-mail: fridtjof.lund-johansen@rr-research.no